D1 dopamine and NMDA receptors interactions in the medial prefrontal cortex: Modulation of spatial working memory in rats

Valentim, Saavedra José Rios; Gontijo, Aline Vidal Lacerda; Peres, Mariana Dadalto; Rodrigues, Lívia Carla de Melo; Nakamura-Palacios, Ester Miyuki

doi:10.1016/j.bbr.2009.05.026

Cited by 18 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since bromocriptine did not affect long-term memory or strategy use, it appears that the 12-arm RAM protocol employed here can identify drugs that selectively affect WMC consistent with observations in humans. The dopamine D1 receptor family agonist SKF 38393 did not improve WMC however, despite improving DD WM performance in rats and non-human primates [20, 21, 23, 24]. This study provides further support for the pharmacological dissociation of DD and WMC performance [6, 13, 15, 64–66].…”

Section: 1 Discussionmentioning

confidence: 53%

“…Bromocriptine was administered intraperitoneally 20 minutes prior to the start of testing in a 10 ml/kg injection volume, with doses chosen based on earlier studies [60, 61]. SKF 38393 (A.G. Scientific, Institute, San Diego, CA), a partial dopamine D1 receptor family agonist was diluted in saline (0.9%) and administered intraperitoneally in a 10 ml/kg injection volume 10 min prior to testing, with doses based on previous studies [20, 62]. Drugs were administered in a cross-over design, with drug treatment on Tuesdays and Fridays, saline on Monday, Wednesday, and Thursday, with a 1-week washout period between drug challenges.…”

Section: 1 Materials and Methodsmentioning

confidence: 99%

“…Much of the research that promotes this receptor as a viable target stems from assessments of D1 agonist effects on delay-dependent (DD) WM in rats and monkeys [20–24]. Given that DD WM and WMC are both pharmacologically and anatomically dissociable, there is little if any evidence that a D1 agonist might improve WMC.…”

Section: 1 Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Working memory span capacity improved by a D2 but not D1 receptor family agonist

Tarantino

Sharp

Geyer

et al. 2011

Behavioural Brain Research

View full text Add to dashboard Cite

Patients with schizophrenia exhibit poor working memory (WM). Although several subcomponents of WM can be measured, evidence suggests the primary subcomponent affected in schizophrenia is span capacity (WMC). Indeed, the NIMH-funded MATRICS initiative recommended assaying the WMC when assessing the efficacy of a putative therapeutic for FDA approval. Although dopamine D1 receptor agonists improve delay-dependent memory in animals, evidence for improvements in WMC due to dopamine D1 receptor activation is limited. In contrast, the dopamine D2-family agonist bromocriptine improves WMC in humans. The radial arm maze (RAM) can be used to assess WMC, although complications due to ceiling effects or strategy confounds have limited its use. We describe a 12-arm RAM protocol designed to assess whether the dopamine D1-family agonist SKF 38393 (0, 1, 3, and 10 mg/kg) or bromocriptine (0, 1, 3, and 10 mg/kg) could improve WMC in C57BL/6N mice (n=12) in cross-over designs. WMC increased and strategy usage decreased with training. The dopamine D1 agonist SKF 38393 had no effect on WMC or long-term memory. Bromocriptine decreased WMC errors, without affecting long-term memory, consistent with human studies. These data confirm that WMC can be measured in mice and reveal drug effects that are consistent with reported effects in humans. Future research is warranted to identify the subtype of the D2-family of receptors responsible for the observed improvement in WMC. Finally, this RAM procedure may prove useful in developing animal models of deficient WMC to further assess putative treatments for the cognitive deficits in schizophrenia.

show abstract

Section: 1 Discussionmentioning

confidence: 53%

Section: 1 Materials and Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Working memory span capacity improved by a D2 but not D1 receptor family agonist

Tarantino

Sharp

Geyer

et al. 2011

Behavioural Brain Research

View full text Add to dashboard Cite

show abstract

“…Executive function is traditionally thought to be affected by DA transmission in the PFC of primates [91,92] and rats [93][94][95], although our recent findings suggest this not to be the case in rats [96]. Administration of E2 increases DA metabolite concentrations in the rat PFC [97] and enhances PFC DA transmission [98].…”

Section: The Prefrontal Cortex (Pfc) and Cognitionmentioning

confidence: 99%

Estrogen and memory system bias in females across the lifespan

Hussain

Shams

Brake

2014

Translational Neuroscience

View full text Add to dashboard Cite

Studies in both rodents and humans have made much progress in shedding light on how fluctuations in ovarian hormones can affect memory in women across the lifespan. Specifically, advances in neuroscience have identified multiple memory systems that are each mediated by different brain areas. Two memory systems used to navigate an environment are 'place' and 'response' memory. They are defined as either using an allocentric strategy: using a spatial or cognitive map of the surroundings, or an egocentric strategy: using habitual-turns/ movements, respectively. Studies in neuroendocrinology have shown that estrogen levels can bias a female to use one memory system over another to solve a task, such that high estrogen levels are associated with using place memory and low levels with using response memory. Furthermore, recent advances in identifying and localizing estrogen receptors in the rodent brain are uncovering which brain regions are affected by estrogen and providing insight into how hormonal fluctuations during the menstrual cycle, pregnancy, and menopause might affect which memory system is facilitated or impaired in women at different life stages. These studies can help point the way to improving cognitive health in women. Estrogen and cognitionModern Western society is not only marked by longer life expectancies, but young women are also waiting longer to have children and having fewer of them, therefore having more menstrual cycles in their lifetimes than ever before. Progesterone (P) and 17β-estradiol (E2; the most potent of the estrogens during reproductive years) vary across the menstrual cycle in a consistent and fluctuating manner.During the first half of the cycle, or follicular phase, E2 and P levels are low; E2 levels then start to increase steadily at the end of menstruation, reaching a peak in the middle of the menstrual cycle, right before ovulation occurs. This is followed by the luteal phase, when E2 levels plateau while P levels increase and peak until menstruation begins again (Figure 1). Thus, E2 and P work hand in hand across a woman's cycle to orchestrate menstruation, ovulation, and conception.However, these hormones appear to be exerting other effects on the female brain, which could be subject to subtle changes as hormone levels fluctuate over time. human menstrual cycle (top panel) and the ~4 day rat estrous cycle (bottom panel). Human menstrual cycle begins with a follicular (mentrual and preovulatory) phase, followed by ovulation, and ends with a luteal phase (spanning end of ovulation to pre-menstrual phase).

show abstract

“…The NORT with naïve rats was used to measure recognition memory (Mumby and Pinel, 1994;Albasser et al, 2009;Rios Valentim et al, 2009). In agreement with previous studies with various PDE10A inhibitors (Grauer et al, 2009;Smith et al, 2013;Jones et al, 2015), TAK-063 at 0.1 and 0.3 mg/kg p.o.…”

Section: Discussionmentioning

confidence: 99%

The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models

Shiraishi

Suzuki

Harada

et al. 2015

Journal of Pharmacology and Experimental Therapeutics

View full text Add to dashboard Cite

Cognitive deficits in various domains, including recognition memory, attention, impulsivity, working memory, and executive function, substantially affect functional outcomes in patients with schizophrenia. TAK-063 [1-[2-fluoro-4-(1H-pyrazol-1-yl) phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4 (1H)-one] is a potent and selective phosphodiesterase 10A inhibitor that produces antipsychotic-like effects in rodent models of schizophrenia. We evaluated the effects of TAK-063 on multiple cognitive functions associated with schizophrenia using naïve and drug-perturbed rodents. TAK-063 at 0.1 and 0.3 mg/kg p.o. improved time-dependent memory decay in object recognition in naïve rats. TAK-063 at 0.1 and 0.3 mg/kg p.o. increased accuracy rate, and TAK-063 at 0.3 mg/kg p.o. reduced impulsivity in a five-choice serial reaction time task in naïve rats. N-methyl-D-aspartate receptor antagonists, such as phencyclidine and MK-801 [(5R,10S)-(1)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine], were used to induce working memory deficits relevant to schizophrenia in animals. TAK-063 at 0.3 mg/kg p.o. attenuated both phencyclidine-induced working memory deficits in a Y-maze test in mice and MK-801-induced working memory deficits in an eight-arm radial maze task in rats. An attentional set-shifting task using subchronic phencyclidine-treated rats was used to assess the executive function. TAK-063 at 0.3 mg/kg p.o. reversed cognitive deficits in extradimensional shifts. These findings suggest that TAK-063 has a potential to ameliorate deficits in multiple cognitive domains impaired in schizophrenia.

show abstract

D1 dopamine and NMDA receptors interactions in the medial prefrontal cortex: Modulation of spatial working memory in rats

Cited by 18 publications

References 26 publications

Working memory span capacity improved by a D2 but not D1 receptor family agonist

Working memory span capacity improved by a D2 but not D1 receptor family agonist

Estrogen and memory system bias in females across the lifespan

The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models

Contact Info

Product

Resources

About